BMKDF (Biomark Diagnostics) Tax Provision : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Biomark Diagnostics Tax Provision?

Biomark Diagnostics's tax provision for the three months ended in Sep. 2024 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Biomark Diagnostics Tax Provision Historical Data

The historical data trend for Biomark Diagnostics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics Tax Provision Chart

Biomark Diagnostics Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Tax Provision

Get a 7-Day Free Trial

Biomark Diagnostics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Tax Provision	Get a 7-Day Free Trial															-	-	-	-	-

Biomark Diagnostics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Biomark Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (OTCPK:BMKDF) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

20B:Germany BUX:Canada

Address

130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2

Website

https://www.biomarkdiagnostics.com

Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.

Biomark Diagnostics Headlines

No Headlines